Pays: Canada
Langue: anglais
Source: Health Canada
DERMATOPHAGOIDES PTERONYSSINUS; DERMATOPHAGOIDES FARINAE
ALK-ABELLO A/S
V01AA03
HOUSE DUST MITES
6UNIT; 6UNIT
TABLET
DERMATOPHAGOIDES PTERONYSSINUS 6UNIT; DERMATOPHAGOIDES FARINAE 6UNIT
SUBLINGUAL
10
Prescription
ALLERGENIC EXTRACTS
Active ingredient group (AIG) number: 0223339003; AHFS:
APPROVED
2017-05-04
_Product Monograph Master Template _ _Template Date: September 2020 _ _ACARIZAX_ _®_ _ Standardized Allergen Extract, House Dust Mites (D. farinae and D. pteronyssinus) _ _Page 1 of 30_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ACARIZAX® Standardized Allergen Extract, House Dust Mites (_D. farinae and D. pteronyssinus_) Sublingual Tablet, 12 SQ-HDM Allergy Immunotherapy Therapeutic classification: Allergen extracts, house dust mite ATC code: V01AA03 ALK-Abelló A/S Bøge Allé 6-8 2970 Hørsholm Denmark http://www.alk.net Date of Initial Authorization: May 04, 2017 Date of Revision: December 29, 2022 Submission Control Number: 241617 _ _ _Product Monograph Master Template _ _Template Date: September 2020 _ _ACARIZAX_ _®_ _ Standardized Allergen Extract, House Dust Mites (D. farinae and D. pteronyssinus) _ _Page 2 of 30_ TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics .......................................................................................................... 4 1.2 Geriatrics........................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 4 4 DOSAGE AND ADMINISTRATION................................................................................. 5 4.1 Dosing Considerations ....................................................................................... 5 4.2 Recommended D Lire le document complet